Cargando…
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer. Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of wh...
Autores principales: | Yang, Jing, Nie, Ji, Ma, Xuelei, Wei, Yuquan, Peng, Yong, Wei, Xiawei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379961/ https://www.ncbi.nlm.nih.gov/pubmed/30782187 http://dx.doi.org/10.1186/s12943-019-0954-x |
Ejemplares similares
-
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
por: Cheng, Yuan, et al.
Publicado: (2019) -
Coronavirus in human diseases: Mechanisms and advances in clinical treatment
por: Lin, Panpan, et al.
Publicado: (2020) -
Molecular mechanisms and clinical management of cancer bone metastasis
por: Wang, Manni, et al.
Publicado: (2020) -
The role of lysosome in regulated necrosis
por: Alu, Aqu, et al.
Publicado: (2020) -
Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3
por: Li, Qingfang, et al.
Publicado: (2022)